Sanofi's Ketek could cause liver problems

A report from the Annals of Internal Medicine warns that Sanofi-Aventis' antibiotic telithromycin Ketek could be linked to liver problems. Doctors at Carolinas Medical Center in Charlotte, NC, said that one patient died as a result of liver failure and another needed a liver transplant. A third patient developed Hepatitis C but later recovered. All three patients were taking the antibiotic Ketek, which was approved by the FDA in 2004. Though the FDA won't make any immediate changes to the drug's warning label, it will continue to monitor adverse events related to the drug.

- read this Wall Street Journal article (sub. req.)